Mast Therapeutics, Inc. (MSTX)

[Rhodey Red]

Mast has plenty of cash on hand to get through EPIC data in Q1'16. After that they will need to raise money for commercialization of Vepoloxamer. Their choices for funding are another secondary offering, use of their existing ATM or the much more preferable, forming a partnership with a larger pharmaceutical company. That last option becomes much more likely once EPIC data is released, they meet their endpoints and move towards FDA approval of Vepoloxamer in SCD.

There isn't an existing shareholder on the planet that yearns for dilutive funding options, but for many micro-cap/small cap biotechs like Mast, it is their only option to fund R-D until they bring a drug successfully through Phase 3 trials and FDA approval.

Mast Is in the home stretch of this process right now.